GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kolon TissueGene Inc (XKRX:950160) » Definitions » EV-to-Revenue

Kolon TissueGene (XKRX:950160) EV-to-Revenue : 643.55 (As of Jun. 04, 2025)


View and export this data going back to 2017. Start your Free Trial

What is Kolon TissueGene EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Kolon TissueGene's enterprise value is ₩3,249,156 Mil. Kolon TissueGene's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was ₩5,049 Mil. Therefore, Kolon TissueGene's EV-to-Revenue for today is 643.55.

The historical rank and industry rank for Kolon TissueGene's EV-to-Revenue or its related term are showing as below:

XKRX:950160' s EV-to-Revenue Range Over the Past 10 Years
Min: 61.04   Med: 134.02   Max: 3965.78
Current: 643.56

During the past 9 years, the highest EV-to-Revenue of Kolon TissueGene was 3965.78. The lowest was 61.04. And the median was 134.02.

XKRX:950160's EV-to-Revenue is ranked worse than
93.98% of 996 companies
in the Biotechnology industry
Industry Median: 7.385 vs XKRX:950160: 643.56

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-06-04), Kolon TissueGene's stock price is ₩39700.00. Kolon TissueGene's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was ₩67.61. Therefore, Kolon TissueGene's PS Ratio for today is 587.20.


Kolon TissueGene EV-to-Revenue Historical Data

The historical data trend for Kolon TissueGene's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kolon TissueGene EV-to-Revenue Chart

Kolon TissueGene Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only 126.19 121.61 59.35 171.30 367.85

Kolon TissueGene Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 171.30 217.50 227.97 212.94 367.85

Competitive Comparison of Kolon TissueGene's EV-to-Revenue

For the Biotechnology subindustry, Kolon TissueGene's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kolon TissueGene's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kolon TissueGene's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Kolon TissueGene's EV-to-Revenue falls into.


;
;

Kolon TissueGene EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Kolon TissueGene's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=3249156.397/5048.783
=643.55

Kolon TissueGene's current Enterprise Value is ₩3,249,156 Mil.
Kolon TissueGene's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩5,049 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kolon TissueGene  (XKRX:950160) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Kolon TissueGene's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=39700.00/67.609
=587.20

Kolon TissueGene's share price for today is ₩39700.00.
Kolon TissueGene's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩67.61.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kolon TissueGene EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Kolon TissueGene's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Kolon TissueGene Business Description

Traded in Other Exchanges
N/A
Address
9713 Key West Avenue, Suite 300, Rockville, MD, USA, 20850
Kolon TissueGene Inc is a biopharmaceutical company that develops regenerative therapies for the treatment of various orthopedic disorders. It is developing four product candidates, TG-C, TG-B, TG-D and TG-N for regeneration of cartilage, bone, disc and nerve.

Kolon TissueGene Headlines

No Headlines